The proposed CTO's Outreach and Dissemination Unit will be led by Apostolia Maria Tsimberidou, M.D.,Ph.D., the proposed Director of Clinical Translation, Education and Outreach, under the guidance of Jason Sakamoto, Ph.D. the proposed CTO Center Manager. Dr. Tsimberidou is an Assistant Professor at MDACC, Department of Investigational Cancer Therapeutics, a Phase I Clinical Trials Program. Dr Sakamoto Is the Chief Operating Officer of the Alliance for NanoHealth (ANH). He will bring to these units his expertise and the already established infrastructure of ANH, including program management, website development and maintenance, pilot and training project development and outreach programs to assist the Outreach and Dissemination Unit. The Outreach and Dissemination Unit will implement initiatives to support the following aims: 1) Disseminate and increase awareness of concepts, capabilities, and results of PS-OC to physical sciences and cancer research communities;and 2) Provide a mechanism to bridge and develop external collaborations. The Outreach and Dissemination aims will be achieved via the following Initiatives: 1. Virtual seminars;2. Workshops with focus topic of Transport OncoPhysics;3. Virtual networking through Interactive websites;and 4. External Pilot projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA143837-06
Application #
8564202
Study Section
Special Emphasis Panel (ZCA1-SRLB-9 (O1))
Project Start
2009-09-28
Project End
2015-07-31
Budget Start
2013-09-19
Budget End
2014-07-31
Support Year
6
Fiscal Year
2013
Total Cost
$198,749
Indirect Cost
$69,691
Name
Methodist Hospital Research Institute
Department
Type
DUNS #
185641052
City
Houston
State
TX
Country
United States
Zip Code
77030
Mai, Junhua; Li, Xin; Zhang, Guodong et al. (2018) DNA Thioaptamer with Homing Specificity to Lymphoma Bone Marrow Involvement. Mol Pharm 15:1814-1825
Krzykawska-Serda, Martyna; Agha, Mahdi S; Ho, Jason Chak-Shing et al. (2018) Chemotherapy and Radiofrequency-Induced Mild Hyperthermia Combined Treatment of Orthotopic Pancreatic Ductal Adenocarcinoma Xenografts. Transl Oncol 11:664-671
Tang, Chad; Hobbs, Brian; Amer, Ahmed et al. (2018) Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep 8:1922
Wang, Feng; Xia, Xiaojun; Yang, Chunying et al. (2018) SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy. Clin Cancer Res 24:3176-3185
Kojic, M; Milosevic, M; Kojic, N et al. (2018) Mass release curves as the constitutive curves for modeling diffusive transport within biological tissue. Comput Biol Med 92:156-167
Koay, Eugene J; Lee, Yeonju; Cristini, Vittorio et al. (2018) A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24:5883-5894
Mu, Chaofeng; Wu, Xiaoyan; Zhou, Xinyu et al. (2018) Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer. Clin Cancer Res 24:4900-4912
Amer, Ahmed M; Zaid, Mohamed; Chaudhury, Baishali et al. (2018) Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer 124:1701-1709
Koay, Eugene J; Hall, William; Park, Peter C et al. (2018) The role of imaging in the clinical practice of radiation oncology for pancreatic cancer. Abdom Radiol (NY) 43:393-403
Martinez, Jonathan O; Molinaro, Roberto; Hartman, Kelly A et al. (2018) Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery. Theranostics 8:1131-1145

Showing the most recent 10 out of 255 publications